Aarti Pharmalabs shareholding pattern

Who owns itSep 2026 quarter

Promoters39.66%−3.20 pts
Foreign investors (FII)8.15%−0.02 pts
Domestic institutions (DII)8.40%+1.18 pts
of which mutual funds0.60%−0.19 pts
of which insurance companies4.75%
Public43.78%

Per cent of all shares; change on the Jun 2026 quarter, in percentage points. As filed with the exchanges.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

AARTIPHARM₹823.65

Aarti Pharmalabs Ltd.

· Pharma & Health
₹ CrorePeersAARTIDRUGSADVENZYMESAGARWALEYEAKUMSALIVUSAPLLTDCORONAHCGMcap ₹7,467 Cr
Holding % of Total Shares
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Q2 FY27
30/09/2026
Promoter & Group46.4646.1044.6644.2943.7242.8843.1043.0842.8639.66
FII / FPI7.067.388.647.367.358.027.688.398.178.15
DII11.4711.3510.367.537.796.967.667.417.228.40
Mutual Funds4.694.933.930.780.900.791.090.800.790.60
Latest: 2026-09-30 · 16 quarters of history · click a row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.